ECSP21080096A - Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra - Google Patents

Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra

Info

Publication number
ECSP21080096A
ECSP21080096A ECSENADI202180096A ECDI202180096A ECSP21080096A EC SP21080096 A ECSP21080096 A EC SP21080096A EC SENADI202180096 A ECSENADI202180096 A EC SENADI202180096A EC DI202180096 A ECDI202180096 A EC DI202180096A EC SP21080096 A ECSP21080096 A EC SP21080096A
Authority
EC
Ecuador
Prior art keywords
treatment
kit
methods
pdgfra
compositions
Prior art date
Application number
ECSENADI202180096A
Other languages
English (en)
Inventor
Timothy Guzi
Thomas Dineen
Joseph Kim
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of ECSP21080096A publication Critical patent/ECSP21080096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción proporciona compuestos de la Fórmula I, sales farmacéuticas de estos y/o solvatos de cualquiera de los anteriores, que son útiles para tratar enfermedades y afecciones relacionadas con KIT y PDGFRa mutantes y presentan un perfil de penetración no cerebral ventajoso para el tratamiento de enfermedades y afecciones relacionadas con KIT y PDGFRa mutantes. La presente descripción proporciona, además, métodos para tratar tumores del estroma gastrointestinal y mastocitosis sistémica.
ECSENADI202180096A 2019-04-12 2021-11-12 Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra ECSP21080096A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
ECSP21080096A true ECSP21080096A (es) 2022-02-25

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180096A ECSP21080096A (es) 2019-04-12 2021-11-12 Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra

Country Status (33)

Country Link
US (2) US12552795B2 (es)
EP (2) EP4424312A3 (es)
JP (2) JP7600140B2 (es)
KR (1) KR102875260B1 (es)
CN (1) CN113939515B (es)
AU (1) AU2020272743B2 (es)
BR (1) BR112021020441A2 (es)
CA (1) CA3136802A1 (es)
CL (1) CL2021002656A1 (es)
CO (1) CO2021015113A2 (es)
DK (1) DK3953357T3 (es)
EC (1) ECSP21080096A (es)
ES (1) ES2980811T3 (es)
FI (1) FI3953357T3 (es)
HR (1) HRP20240702T1 (es)
HU (1) HUE067299T2 (es)
IL (1) IL287168B2 (es)
LT (1) LT3953357T (es)
MA (1) MA55604B1 (es)
MD (1) MD3953357T2 (es)
MX (1) MX2021012469A (es)
MY (1) MY209048A (es)
PE (1) PE20212331A1 (es)
PH (1) PH12021552568A1 (es)
PL (1) PL3953357T3 (es)
PT (1) PT3953357T (es)
RS (1) RS65644B1 (es)
SG (1) SG11202111244XA (es)
SI (1) SI3953357T1 (es)
SM (1) SMT202400229T1 (es)
TW (1) TWI857043B (es)
WO (1) WO2020210293A1 (es)
ZA (1) ZA202108104B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7710223B2 (ja) * 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
SI3953357T1 (sl) * 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
WO2022081626A1 (en) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
WO2022081627A1 (en) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
BR112023017780A2 (pt) 2021-03-03 2023-11-21 Blueprint Medicines Corp Métodos sintéticos e intermediários para produção de compostos para tratamento de doenças mediadas por kit e pdgfra
KR20240013720A (ko) * 2021-03-10 2024-01-30 블루프린트 메디신즈 코포레이션 키나아제 저해제의 염 및 고체 형태
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
WO2023081923A1 (en) * 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024171143A1 (en) * 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
BR0309669A (pt) 2002-04-23 2005-03-01 Bristol Myers Squibb Co Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005115397A2 (en) 2004-04-29 2005-12-08 Pharmix Corporation Compositions and treatments for modulating kinase and/or hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5256047B2 (ja) 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤
WO2008005956A2 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
US20130023497A1 (en) 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2789711C (en) 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
SG195100A1 (en) 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102212923B1 (ko) 2012-12-21 2021-02-04 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
PT3409674T (pt) 2013-10-17 2022-07-18 Blueprint Medicines Corp Processo para preparar composições úteis para tratar distúrbios relacionados com kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2018106483A (ru) 2015-07-24 2019-08-26 Блюпринт Медсинс Корпорейшн Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
JP7710223B2 (ja) 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
US20210261512A1 (en) 2018-05-04 2021-08-26 Inflazome Limited Novel compounds
TW202039862A (zh) 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
CA3123829A1 (en) 2018-12-20 2020-06-25 Pfizer Inc. Polymorphic forms of 4-(2-(5-chloro-2-flourophenyl)-5-isopropylpyridin-4-ylamino)-n-(1,3-dihydroxypropan-2-yl)nicotinamide
SI3953357T1 (sl) * 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
WO2022081626A1 (en) 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases

Also Published As

Publication number Publication date
EP4424312A2 (en) 2024-09-04
JP2025029094A (ja) 2025-03-05
PT3953357T (pt) 2024-07-24
MY209048A (en) 2025-06-18
MA55604A (fr) 2022-02-16
MA55604B1 (fr) 2024-08-30
AU2020272743B2 (en) 2025-10-16
TWI857043B (zh) 2024-10-01
ES2980811T3 (es) 2024-10-03
US12552795B2 (en) 2026-02-17
US20220153748A1 (en) 2022-05-19
FI3953357T3 (fi) 2024-07-15
IL287168B1 (en) 2025-06-01
HUE067299T2 (hu) 2024-10-28
EP3953357A1 (en) 2022-02-16
JP7600140B2 (ja) 2024-12-16
JP2022526850A (ja) 2022-05-26
MX2021012469A (es) 2022-01-18
KR102875260B1 (ko) 2025-10-23
HRP20240702T1 (hr) 2024-08-16
CN113939515A (zh) 2022-01-14
BR112021020441A2 (pt) 2021-12-14
PE20212331A1 (es) 2021-12-14
CO2021015113A2 (es) 2022-02-28
EP4424312A3 (en) 2025-01-08
WO2020210293A1 (en) 2020-10-15
SMT202400229T1 (it) 2024-07-09
ZA202108104B (en) 2024-02-28
CA3136802A1 (en) 2020-10-15
EP3953357B1 (en) 2024-04-17
PL3953357T3 (pl) 2024-09-02
AU2020272743A1 (en) 2021-11-11
IL287168A (en) 2021-12-01
CN113939515B (zh) 2024-06-18
SI3953357T1 (sl) 2024-08-30
CL2021002656A1 (es) 2022-08-26
TW202104231A (zh) 2021-02-01
DK3953357T3 (en) 2024-06-10
KR20220025704A (ko) 2022-03-03
IL287168B2 (en) 2025-10-01
US20200325141A1 (en) 2020-10-15
PH12021552568A1 (en) 2022-07-04
RS65644B1 (sr) 2024-07-31
SG11202111244XA (en) 2021-11-29
LT3953357T (lt) 2024-07-25
US10829493B2 (en) 2020-11-10
MD3953357T2 (ro) 2024-09-30

Similar Documents

Publication Publication Date Title
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
CL2024002398A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas (divisional de solicitud no. 202001931)
NI202100027A (es) Inhibidores de la proteína tirosina fosfatasa
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2020007383A (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2017001126A1 (es) Agentes inmunoreguladores
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
EA202191519A1 (ru) Модуляторы trex1
UA116469C2 (uk) Похідні тамоксифену для лікування новоутворень, особливо з високим рівнем білка her2
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
MX2018008157A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2024002173A (es) Compuestos de arilsulfonilo como inhibidores de ccr6.
CY1124308T1 (el) Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak
AR119557A1 (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1